摘要
目的:观察岩舒注射液联合化疗治疗晚期大肠癌的临床疗效。方法:68例晚期大肠癌患者随机分为化疗组(对照组)和化疗联合岩舒组(试验组),其中试验组36例奥沙利铂130mg/m2+5%GS250ml静滴,d1;亚叶酸钙(CF)100mg+5%GS250ml静滴,d1～d5;氟尿嘧啶0.5g(5-Fu)+5%GS500ml静滴,d1～d5。化疗当天给予岩舒注射液40ml+5%GS250ml静滴,d1～d20,常规给予5-HT3受体抑制剂止吐,21天为1周期。对照组32例,化疗方法同治疗组。结果:试验组有效率为63.9%,对照组有效率为40.6%,治疗组有效率明显高于对照组,差异有显著意义(P<0.05);对照组白细胞减少为75%,高于试验组的52.8%。结论:岩舒注射液联合化疗可显著提高化疗疗效,增强机体免疫功能,改善患者的生存质量,且不增加对骨髓的抑制。
OBJECTIVE： To observe the curative efficacy .of yanshu plus chemotherapy for advanced carcinoma of large intestine. METHODS： A total of 68 patietns with advanced carcinoma of large intestine were enrolled, 36 were randomized to trial group （chemotherapy plus yanshu） and 32 to control group （chemotherapy）. Patients in the trial group were intravenously infused with oxaliplatin 130mg/m^2 diluted in 5 % 250ml of GS on day 1, calcium folinate （CF） 100mg diluted in 5% 250ml of GS and fluorouracil 0.5g （5 - Fu） diluted in 5% 250ml of GS for the first 5 days, besides, yanshu injection 40 ml diluted in 5 % 250ml of GS was administered concurrently with chemotherapy from day 1 to day 20, and 5 - HT3 receptor inhibitors （antiemetic） were administered routinely （1 cycle was defined as 21 days）. The chemotherapy adopted in the control group was the same as in the trial group. RESULTS： The responsive rates of the trial group were significantly higher than in the control group （63.9% vs. 40.6% ）, and there were significances between 2 groups （P 〈0.05）; the WBC reduction rates in the control group was higher than in the trial group （75% vs. 53.8%）. CONCLUSION： Yanshu plus chemotherapy can enhance efficacy of chemotherapy, strengthen immunologic function and improve life quality of patients yet without increasing the bone marrow depression.
出处
《中国医院用药评价与分析》
2007年第1期64-65,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
晚期大肠癌
岩舒
疗效观察
advanced carcinoma of large intestine
yanshu
observation of curative effects
